Betamethasone valerate Pharmacology 

Betamethasone valerate
Betamethasone valerate
It is a topical steroid
It is a topical steroid
The drug exerts it`s pharmacological action by penetrating and binding to cytoplasmic receptor protein and causes a structural change in steroid receptor complex. This structural change allows it`s migration in to the nucleus and then binding to specific sites on the DNA which leads to transcription of specific m-RNA and which ultimately regulates protein synthesis. It exerts highly selective glucocorticoid action. It stimulates the enzymes needed to decrease the inflammatory response.
The drug exerts anti-inflammatory and immunosuppressant actions as follows: – 1) Induce lipocortins in macrophages, endothelium, and fibroblasts which inhibits phospholipase A2 and thus decreases the production of Prostaglandins, leukotriens (LT), and platelet activating factor, 2) Causes negative regulation of genes for cytokines in macrophages, endothelial cells and lymphocytes and thus decreases the production of interleukins (IL-1, IL-2, IL-3, IL-6), TNF-alpha, GM-CSF (granulocyte macrophage colony stimulating factor), Gama interferon and suppresses fibroblast proliferation and T-lymphocyte functions and interferes chemotaxis. 3) Decreases the production of acute phase reactants from macrophages and endothelial cells and interferes complement function. 4) Decreases the production of ELAM-1(Endothelial leukocyte adhesion molecule-1) and ICAM- 1(intracellular adhesion molecule-1) in endothelial cells. 5) Inhibit IgE mediated histamine and LT-C4 release from basophiles and the effects of antigen-antibody reaction is not mediated 6) Reduces the production of
collagenase and stromolysin and thus prevents tissue destruction.
The drug exerts it`s pharmacological action by penetrating and binding to cytoplasmic receptor protein and causes a structural change in steroid receptor complex. This structural change allows it`s migration in to the nucleus and then binding to specific sites on the DNA which leads to transcription of specific m-RNA and which ultimately regulates protein synthesis. It exerts highly selective glucocorticoid action. It stimulates the enzymes needed to decrease the inflammatory response.
The drug exerts anti-inflammatory and immunosuppressant actions as follows: – 1) Induce lipocortins in macrophages, endothelium, and fibroblasts which inhibits phospholipase A2 and thus decreases the production of Prostaglandins, leukotriens (LT), and platelet activating factor, 2) Causes negative regulation of genes for cytokines in macrophages, endothelial cells and lymphocytes and thus decreases the production of interleukins (IL-1, IL-2, IL-3, IL-6), TNF-alpha, GM-CSF (granulocyte macrophage colony stimulating factor), Gama interferon and suppresses fibroblast proliferation and T-lymphocyte functions and interferes chemotaxis. 3) Decreases the production of acute phase reactants from macrophages and endothelial cells and interferes complement function. 4) Decreases the production of ELAM-1(Endothelial leukocyte adhesion molecule-1) and ICAM- 1(intracellular adhesion molecule-1) in endothelial cells. 5) Inhibit IgE mediated histamine and LT-C4 release from basophiles and the effects of antigen-antibody reaction is not mediated 6) Reduces the production of
collagenase and stromolysin and thus prevents tissue destruction.
Absorption: It is absorbed in to the systemic circulation and the amount is depending on the potency, amount
applied and the nature of the skin at the site of application. Absorption increases at the site of skin damage, inflammation or occlusion.
Absorption: It is absorbed in to the systemic circulation and the amount is depending on the potency, amount
applied and the nature of the skin at the site of application. Absorption increases at the site of skin damage, inflammation or occlusion.
Absorption: It is absorbed in to the systemic circulation and the amount is depending on the potency, amount
applied and the nature of the skin at the site of application. Absorption increases at the site of skin damage, inflammation or occlusion.
Absorption: It is absorbed in to the systemic circulation and the amount is depending on the potency, amount
applied and the nature of the skin at the site of application. Absorption increases at the site of skin damage, inflammation or occlusion.
N/A
N/A
N/A
N/A
1.Thinning of the skin 2.Loss of elasticity 3.Increased hair growth
4.Acne at the site of application 5.Mild depigmentation
6.Rosacea
1.Thinning of the skin 2.Loss of elasticity 3.Increased hair growth
4.Acne at the site of application 5.Mild depigmentation
6.Rosacea
1.Untreated bacterial, virus or fungal infections 2.Acne vulgaris,
3.Peri-oral dermatitis, 4.Scabies,
5.Leg ulcers, 6.Tuberculosis of the skin, 7.Varicose ulcers,
8.Skin lesions caused by infections with ring worm,. fungi (e.g. Candida, Tinea) or bacteria (e.g. impetigo) 9.Hypersensitivity to Betamethasone and other corticosteroids.
10.Discoid lupus Erythematosus
1.Untreated bacterial, virus or fungal infections 2.Acne vulgaris,
3.Peri-oral dermatitis, 4.Scabies,
5.Leg ulcers, 6.Tuberculosis of the skin, 7.Varicose ulcers,
8.Skin lesions caused by infections with ring worm,. fungi (e.g. Candida, Tinea) or bacteria (e.g. impetigo) 9.Hypersensitivity to Betamethasone and other corticosteroids.
10.Discoid lupus Erythematosus
1.Avoid contact with eyes 2.For external use only
3.Prolonged use
1.Avoid contact with eyes 2.For external use only
3.Prolonged use
Use with caution
Use with caution
Use with caution
Use with caution
Use with caution
Use with caution
Use with caution
NEONATES: contraindicated
Use with caution
NEONATES: contraindicated
1.Psoriasis, 2.Eczema, 3.Otitis externa,
4.Lichen simplex and planus, 5.Anal and vulval Pruritis, 6.Seborrheic dermatitis, 7.Contact dermatitis,
8.Steroidal responsive dermatoses of the scalp
1.Psoriasis, 2.Eczema, 3.Otitis externa,
4.Lichen simplex and planus, 5.Anal and vulval Pruritis, 6.Seborrheic dermatitis, 7.Contact dermatitis,
8.Steroidal responsive dermatoses of the scalp
N/A
N/A
Topical:
Betamethasone Valerate: Apply to the affected area as thin film 1 – 4 times daily depending upon the severity, skin and rate of absorption.
Dermatoses of the scalp: (Betamethasone Valerate 0.12%): Small amount of foam is applied in to the scalp with
gentle massage 2 times a day for up to 2 weeks.
Topical:
Betamethasone Valerate: Apply to the affected area as thin film 1 – 4 times daily depending upon the severity, skin and rate of absorption.
Dermatoses of the scalp: (Betamethasone Valerate 0.12%): Small amount of foam is applied in to the scalp with
gentle massage 2 times a day for up to 2 weeks.
N/A
N/A
Store at room temperature in a well closed; light resistant container. Protect from excess heat and moisture.
Keep out of reach of children.
Store at room temperature in a well closed; light resistant container. Protect from excess heat and moisture.
Keep out of reach of children.
Apply the missed dose as soon as noticed and if it is the time for next dose then skip the missed dose. Continue
the regular schedule. Do not double the dose.
Apply the missed dose as soon as noticed and if it is the time for next dose then skip the missed dose. Continue
the regular schedule. Do not double the dose.